Patents Represented by Attorney, Agent or Law Firm Richard P. Ryan
  • Carbohydrate prodrugs of fluorooxindoles
    Patent number: 6916937
    Abstract: The present invention provides novel prodrug derivatives of fluorooxindoles having the general Formula I wherein the wavy bond () represents the racemate, the (R)-enantiomer or the (S)-enantiomer, and R1, R2, R3, R4 and X are as defined herein, or a nontoxic pharmaceutically acceptable salt or solvate thereof and are useful in the treatment of disorders which are responsive to the opening of potassium channels.
    Type: Grant
    Filed: January 22, 2004
    Date of Patent: July 12, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kevin Gillman, Danielle M. Bocchino
  • S-6-hydroxy-buspirone
    Patent number: 6821976
    Abstract: The S-stereoisomer of 6-hydroxy-buspirone is an effective treatment for anxiety, depression, and other psychogenic disorders. The S-isomer may provide reduced potential for adverse effects and a longer duration of action compared to the racemic mixture and with buspirone.
    Type: Grant
    Filed: July 22, 2002
    Date of Patent: November 23, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joseph P. Yevich, Robert F. Mayol, Jianqing Li, Frank Yocca
  • R-6-hydroxy-buspirone
    Patent number: 6686361
    Abstract: The R-stereoisomer of 6-hydroxy-buspirone is an effective treatment for anxiety, depression, and other psychogenic disorders. The R-isomer exhibits greater receptor specificity than the S-isomer and should have reduced potential for the adverse effects associated with the racemic mixture and with buspirone.
    Type: Grant
    Filed: July 22, 2002
    Date of Patent: February 3, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joseph P. Yevich, Robert F. Mayol, Jianqing Li, Frank Yocca
  • Oxadiazole and thiadiazole derivatives of dihydropyridine NPY antagonists
    Patent number: 6596724
    Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of oxadiazole, thiadiazole and thiadiazole oxide derivatives of dihydropyridines of Formula I. wherein B is with X being O, S or and X1 is O or S. As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: July 2, 2001
    Date of Patent: July 22, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Graham S. Poindexter, Mendi Higgins, James Guy Breitenbucher
  • Method for treatment of pain
    Patent number: 6593331
    Abstract: A method of treating pain with acetaminophen comprises the concurrent administration of a hydroxyazapirone selected from 6-hydroxybuspirone or 3-hydroxygepirone. This combination of agents results in a more morphine-like analgesic response characterized by rapid onset and greater pain relief.
    Type: Grant
    Filed: April 4, 2002
    Date of Patent: July 15, 2003
    Assignees: Laboratories UPSA, Bristol-Myers Squibb Company
    Inventors: Francoise Camborde, Alix Cloarec, Charles Conway
  • Azapirone pain treatment
    Patent number: 6566361
    Abstract: A method of treating pain with acetaminophen comprises the concurrent administration of an azapirone such as buspirone. This combination of agents surprisingly results in a strengthened analgesic response characterized by rapid onset, greater pain relief, and a longer duration of action.
    Type: Grant
    Filed: May 17, 2001
    Date of Patent: May 20, 2003
    Assignees: Laboratories, UPSA, Bristol-Myers Squibb Company
    Inventors: Francoise Camborde, Alix Cloarec, Charles Conway
  • Treatment of pain
    Patent number: 6511982
    Abstract: A method of treating pain with acetaminophen comprises the concurrent administration of buspirone. This combination of agents surprisingly results in a morphine-like analgesic response characterized by rapid onset, greater pain relief, and a longer duration of action.
    Type: Grant
    Filed: January 4, 2001
    Date of Patent: January 28, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Francoise Camborde, Alix Cloarec, Charles Conway
  • Alkylamine derivatives of dihydropyridine NPY antagonists
    Patent number: 6479482
    Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprises of amino and piperazine derivatives of 4-phenyl-1,4-dihydropyridines of Formula 1. where X is CH or N As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: May 10, 2001
    Date of Patent: November 12, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Graham S. Poindexter, Marc Bruce, Sing-Yuen Sit, Scott W. Martin
  • Antipsychotic heterocycle compounds
    Patent number: 6476051
    Abstract: Compounds of Formula I: wherein Ar, Y, m, and Z are as defined in the specification, are useful antipsychotic and antidepressant agents demonstrating potent inhibition of 5-HT reuptake and dopamine D2 receptor antagonism.
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: November 5, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ronald J. Mattson, Joseph P. Yevich, Jun Yuan, Arlene S. Eison, Derek Denhart
  • 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists
    Patent number: 6444675
    Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of 4-alkyl and cycloalkyl derivatives of dihydropyridines of Formula I. As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: September 3, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventor: Sing-Yuen Sit
  • Method for treatment of sleep apneas
    Patent number: 6432956
    Abstract: Certain azapirone compounds and their pharmaceutically acceptable salts are useful in the treatment of sleep apneas.
    Type: Grant
    Filed: May 3, 1991
    Date of Patent: August 13, 2002
    Inventors: William C. Dement, Mark R. Rosekind, Jeffrey L. Schwimmer
  • Squarate derivatives of dihydropyridine NPY antagonists
    Patent number: 6432960
    Abstract: A series of antagonists of NPY have been synthesized and are comprised of squarate derivatives of 4-phenyl-1,4-dihydropyridines of Formula (I). As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: August 13, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sing-Yuen Sit, Graham S. Poindexter
  • Benzodiazepinone &bgr;-amyloid inhibitors: arylacetamidoalanyl derivatives
    Patent number: 6432944
    Abstract: There is provided a series of arylacetamidoalanyl derivatives of benzodiazepinones of Formula I wherein R1 through R7 and n are defined herein, which are inhibitors of &bgr;-amyloid peptide (&bgr;-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions characterized by aberrant extract cellular deposition of amyloid.
    Type: Grant
    Filed: July 2, 2001
    Date of Patent: August 13, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Prasad V. Chaturvedula, Suresh Yeola, Shikha Vig
  • Thiourea derivatives of dihydropyridine NPY antagonists
    Patent number: 6391881
    Abstract: A series of antagonists of NPY have been synthesized and are comprised of thiourea linked piperazine and piperidine derivatives of 4-phenyl-1,4-dihydropyridines of Formula 1. where Z is NR7R8 or and X is CH or N. As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: May 21, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventor: Sing-Yuen Sit
  • Method for treatment of anxiety and depression
    Patent number: 6312717
    Abstract: An improved method of treatment for anxiety and/or depression provides a quicker and more robust anxiolytic/antidepressant activity to a patient suffering from depression. The method comprises the concurrent administration of effective doses of certain azapirones, such as buspirone, given in a manner that suppresses formation of the 1-(2-pyrimidinyl)piperazine metabolite; and a 5-HT1A autosomal receptor antagonist, such as pindolol.
    Type: Grant
    Filed: June 14, 1999
    Date of Patent: November 6, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: Perry B. Molinoff, Geoffrey C. Dunbar
  • Antidepressant heterocyclic compounds
    Patent number: 6225324
    Abstract: Compounds of formula I are useful antidepressant agents demonstrating potent inhibition of 5-HT reuptake. Z is selected from among various phenyl and hetaryl moieties while Y is benzyl or indolyl.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: May 1, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael A. Poss, David R. Tortolani, Ronald J. Mattson, Joseph P. Yevich
  • Anxiety method
    Patent number: 6150365
    Abstract: 6-Hydroxy-8-[4-[4-(2-pyrimidinyl)-piperazinyl]-butyl]-8-azaspiro[4.5]-7,9-d ione and its pharmaceutically acceptable salts and hydrates are useful in the alleviation of anxiety.
    Type: Grant
    Filed: June 6, 2000
    Date of Patent: November 21, 2000
    Assignee: Bristol-Myers Squibb Company
    Inventor: Robert F. Mayol
  • Nefazodone dosage form
    Patent number: 6143325
    Abstract: Extended-release nefazodone compositions containing nefazodone hydrochloride, ionic and non-ionic gelling polymers, an insoluble hydrophilic agent, and optional pharmaceutically acceptable excipients demonstrate pH-modulated release of nefazodone. These compositions are formulated into unit dosage forms for improved oral administration. The improvements comprise an extended drug release profile providing comparative levels of nefazodone with respect to immediate release dosage forms and, additionally, demonstrating the lack of a food effect.
    Type: Grant
    Filed: April 26, 1999
    Date of Patent: November 7, 2000
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew B. Dennis, Peter Timmins, Alison C. Hodsdon
  • Imidazolone anorectic agents: III. heteroaryl derivatives
    Patent number: 6096745
    Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of heteroaryl derivatives of imidazolone compounds of Formula 1. ##STR1## As antagonists of NPY-induced feeding behavior, these compounds and known analogs are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: March 3, 1999
    Date of Patent: August 1, 2000
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Graham S. Poindexter, Kevin Gillman
  • Aryloxyanilides and related compounds
    Patent number: 6090854
    Abstract: There is provided novel aryloxyanilides and related compounds of the formula ##STR1## wherein R.sup.1 is --OR, --CO.sub.2 R, or halogen with R being C.sub.1-4 alkyl;R.sup.2 is R, cyclopropyl, C.sub.2-4 alkenyl or --CH.sub.2 OR; andX is O, S, CH.sub.2, NR, SO, SO.sub.2 or COwhich are melatonergic agents and are useful in the treatment of circadian rhythm-related disorders and other conditions affected by melatonin activity.
    Type: Grant
    Filed: January 22, 1999
    Date of Patent: July 18, 2000
    Assignee: Bristol-Meyers Company
    Inventor: James R. Epperson